|
27 Oct 2022 |
Ultomiris showed zero relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) with median treatment duration of 73 weeks
|
|
27 Oct 2022 |
GSK provides update on ContRAst phase III programme for otilimab in the treatment of moderate to severe rheumatoid arthritis
|
|
27 Oct 2022 |
CSL enters into Strategic Option and License Agreement with Translational Sciences
|
|
27 Oct 2022 |
ESSA Pharma Presents Preclinical Data for its First Generation Androgen Receptor N-Terminal Domain Degrader at the 34th EORTC-NCI-AACR Symposium
|
|
27 Oct 2022 |
Nykode Therapeutics Announces Presentation of Positive Immunogenicity Results from Phase 1/2a Study of VB10.NEO, an Individualized Therapeutic Cancer Vaccine, at the Neoantigen-Based Therapies Summit
|
|
27 Oct 2022 |
Corvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell Cancer
|
|
27 Oct 2022 |
Foghorn Therapeutics Announces New Data Demonstrating BRD9 Degradation in Patient Tumor Biopsies and Discloses New Selective CBP Program
|
|
27 Oct 2022 |
Positive Topline Phase III Results Show Genentech’s Vabysmo Improved Vision for People Living With Retinal Vein Occlusion (RVO)
|
|
26 Oct 2022 |
eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19
|
|
26 Oct 2022 |
Codagenix Initiates Dosing in Phase 3 Efficacy Trial of Intranasal COVID-19 Vaccine as Part of WHO-Sponsored Solidarity Trial Vaccines
|
|
26 Oct 2022 |
Boehringer Ingelheim enrolls first patient in Phase III trial of BI 1015550 in idiopathic pulmonary fibrosis
|
|
26 Oct 2022 |
Ascletis Announces U.S. IND Filing of Oral Antiviral ASC10 for Monkeypox Indication
|
|
26 Oct 2022 |
Orionis Biosciences Demonstrates Platform Capabilities of Genome-scale Molecular Glue Discovery and Rational Design at Targeted Protein Degradation Summit
|
|
26 Oct 2022 |
Radiopharm Theranostics Signs Agreement With NorthStar Medical Radioisotopes for the Supply of Non-Carrier Added (n.c.a.) Actinium-225
|
|
26 Oct 2022 |
Candel Therapeutics Partners with the University of Pennsylvania’s Center for Cellular Immunotherapies to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy in Solid Tumor Models
|
|
26 Oct 2022 |
Merus Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics
|
|
26 Oct 2022 |
RZNOMICS Inc. received FDA approval to initiate clinical development of trans-splicing ribozyme-based RNA editing technology in liver cancer patients
|
|
26 Oct 2022 |
Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University
|
|
26 Oct 2022 |
Adaptimmune Enhances Its Pipeline of Wholly Owned Cell Therapies for Cancer with Transfer of PRAME and NY-ESO Target Programs from GSK
|
|
26 Oct 2022 |
Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha’s AAV-based Gene Therapy Programs
|
